EB-001

Bonti, Inc. · Phase 2 active Small molecule

At a glance

Generic name	EB-001
Also known as	Botulinun Toxin Type E
Sponsor	Bonti, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty (PHASE2)
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines (PHASE2)
Study to Evaluate EB-001 in Reducing Musculoskeletal Pain (PHASE2)
Study of EB-001 in Facial Scar Reduction (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EB-001 CI brief — competitive landscape report
EB-001 updates RSS · CI watch RSS
Bonti, Inc. portfolio CI